; or (ii) for which a shortage would be most likely to have the greatest potential adverse health consequences; (C) in applying subparagraph (B), shall count as a single medication— (i) all strengths, dosage forms, and package forms of a given medication; (ii) medications that are therapeutically equivalent (under the Food and Drug Administration’s most recent publication of Approved Drug Products with Therapeutic Equivalence Evaluations ); and (iii) a biological product licensed under section 351(a) and all biosimilar biological products that are licensed under section 351(k) using the biological product as the reference product; and (D) in applying subparagraph (B), shall not prioritize the inclusion of any medication that is a qualified countermeasure (as defined in section 319F–1(a)(2)), a security countermeasure (as defined in section 319F–2(c)(1)(B)), or a qualified pandemic and epidemic product (as defined in section 319F–3(i)). (6) Public input and comment In developing and updating the list under paragraph (1), the Secretary shall solicit public input, including by— (A) consulting (through public meetings or other forms of engagement) with relevant stakeholders, including health care providers, medical professional societies, public health experts, State and local public health departments, patient groups, and drug manufacturers and distributors; (B) publishing in the Federal Register, for public review and comment, the Secretary’s proposed list of critical medications, together with the Secretary’s reasons why each medication included on such proposed list was included and the reasons why other medications were not included; (C) accepting public comment on such proposed list and reasons for a period of not less than 60 days; (D) taking such comments into account in determining the final list under paragraph (1)